Sex and gender disparities in patients with advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry

Siegel, 2020, Cancer statistics, 2020, CA Cancer J Clin, 70, 7, 10.3322/caac.21590 Maestre, 2020, On the basis of sex and gender in healthcare, Spanish J Med, 1 Dijksterhuis, 2021, Gender differences in treatment allocation and survival of advanced gastroesophageal cancer: a population-based study, J Nat Cancer Inst, 113, 1551, 10.1093/jnci/djab075 Poorolajal, 2020, Risk factors for stomach cancer: a systematic review and meta-analysis, Epidemiol Health, 42, 10.4178/epih.e2020004 Custodio, 2017, Nomogram-based prediction of survival in patients with advanced oesophagogastric adenocarcinoma receiving first-line chemotherapy: a multicenter prospective study in the era of trastuzumab, Br J Cancer, 116, 1526, 10.1038/bjc.2017.122 Alvarez-Manceñido, 2021, Is advanced esophageal adenocarcinoma a distinct entity from intestinal subtype gastric cancer? Data from the AGAMENON-SEOM Registry, Gastric Cancer, 24, 926, 10.1007/s10120-021-01169-6 Kim, 2016, Sex disparity in gastric cancer: female sex is a poor prognostic factor for advanced gastric cancer, Ann Surg Oncol, 23, 4344, 10.1245/s10434-016-5448-0 Bohanes, 2012, Influence of sex on the survival of patients with esophageal cancer, J Clin Oncol, 30, 2265, 10.1200/JCO.2011.38.8751 Peters, 2018, Sex and gender reporting in global health: new editorial policies, BMJ Glob Health, 3, 10.1136/bmjgh-2018-001038 Heidari, 2016, Sex and Gender Equity in Research: rationale for the SAGER guidelines and recommended use, Res Integr Peer Rev, 1, 2, 10.1186/s41073-016-0007-6 Clayton, 2016, Reporting sex, gender, or both in clinical research?, JAMA, 316, 1863, 10.1001/jama.2016.16405 Petkovic, 2018, Sex/gender reporting and analysis in Campbell and Cochrane systematic reviews: a cross-sectional methods study, Syst Rev, 7, 113, 10.1186/s13643-018-0778-6 Chen, 2018, Representation of women and minorities in clinical trials for new molecular entities and original therapeutic biologics approved by FDA CDER from 2013 to 2015, J Womens Health (Larchmt), 27, 418, 10.1089/jwh.2016.6272 Wagner, 2019, Gender medicine and oncology: report and consensus of an ESMO workshop, Ann Oncol, 30, 1914, 10.1093/annonc/mdz414 Carmona-Bayonas, 2022, Causal considerations can inform the interpretation of surprising associations in medical registries, Cancer Invest, 40, 1, 10.1080/07357907.2021.1999971 Jimenez-Fonseca, 2021, External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit?, Gastric Cancer, 24, 445, 10.1007/s10120-020-01116-x Carmona-Bayonas, 2018, Anthracycline-based triplets do not improve the efficacy of platinum-fluoropyrimidine doublets in first-line treatment of advanced gastric cancer: real-world data from the AGAMENON National Cancer Registry, Gastric Cancer, 21, 96, 10.1007/s10120-017-0718-5 Jiménez Fonseca, 2017, Lauren subtypes of advanced gastric cancer influence survival and response to chemotherapy: real-world data from the AGAMENON National Cancer Registry, Br J Cancer, 117, 775, 10.1038/bjc.2017.245 Zaragoza-Huesca, 2022, Identification of thrombosis-related genes in patients with advanced gastric cancer: data from AGAMENON-SEOM registry, Biomedicines, 10, 148, 10.3390/biomedicines10010148 Cotes Sanchís, 2020, Second-line treatment in advanced gastric cancer: Data from the Spanish AGAMENON registry, PLoS One, 15, 10.1371/journal.pone.0235848 Jimenez-Fonseca, 2021, External validity of clinical trials with diverse trastuzumab-based chemotherapy regimens in advanced gastroesophageal adenocarcinoma: data from the AGAMENON-SEOM registry, Ther Adv Med Oncol, 13, 10.1177/17588359211019672 Carmona-Bayonas, 2018, Surgery for metastases for esophageal-gastric cancer in the real world: data from the AGAMENON national registry, Eur J Surg Oncol, 44, 1191, 10.1016/j.ejso.2018.03.019 Carmona-Bayonas, 2019, Multistate models: accurate and dynamic methods to improve predictions of thrombotic risk in patients with cancer, Thromb Haemost, 119, 1849, 10.1055/s-0039-1694012 Visa, 2017, Efficacy and safety of chemotherapy in older versus non-older patients with advanced gastric cancer: A real-world data, non-inferiority analysis, J Geriatr Oncol, 9, 254, 10.1016/j.jgo.2017.11.008 Jiménez-Fonseca, 2017, Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer, Gastric Cancer, 20, 465, 10.1007/s10120-016-0639-8 Carmona-Bayonas, 2016, On the effect of triplet or doublet chemotherapy in advanced gastric cancer: results from a national cancer registry, JNCCN J Natl Compr Cancer Netw, 14, 1379, 10.6004/jnccn.2016.0148 2014 Therneau Özdemir, 2022, Investigation of sex and gender differences in oncology gains momentum: ESMO announces the launch of a Gender Medicine Task Force, Ann Oncol, 33, 126, 10.1016/j.annonc.2021.11.011 Lou, 2020, Sex difference in incidence of gastric cancer: an international comparative study based on the Global Burden of Disease Study 2017, BMJ Open, 10, 10.1136/bmjopen-2019-033323 Machlowska, 2020, Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies, Int J Mol Sci, 21, 4012, 10.3390/ijms21114012 Mine, 2006, Early-onset gastric cancers have a different molecular expression profile than conventional gastric cancers, Mod Pathol, 19, 564, 10.1038/modpathol.3800563 2014, Comprehensive molecular characterization of gastric adenocarcinoma, Nature, 513, 202, 10.1038/nature13480 Rijken, 2021, The burden of peritoneal metastases from gastric cancer: a systematic review on the incidence, risk factors and survival, J Clin Med, 10, 4882 Wang, 2014, Gender differences in survival and the use of primary care prior to diagnosis of three cancers: an analysis of routinely collected UK general practice data, PLoS One, 9 Wagner, 2017, Chemotherapy for advanced gastric cancer, Cochrane Database Syst Rev, 8, CD004064 George, 2021, Physical comorbidities and their relationship with cancer treatment and its outcomes in older adult populations: systematic review, JMIR Cancer, 7, 10.2196/26425 Lee, 2011, Impact of comorbidity on chemotherapy use and outcomes in solid tumors: a systematic review, J Clin Oncol, 29, 106, 10.1200/JCO.2010.31.3049 Sugarbaker, 2018, Gastric cancer: prevention and treatment of peritoneal metastases, J Cancer Metastasis Treat, 4, 7, 10.20517/2394-4722.2017.67 Rau, 2021, The effect of hyperthermic intraperitoneal chemotherapy (HIPEC) upon cytoreductive surgery in gastric cancer with synchronous peritoneal metastasis: a randomized multicentre phase III trial (GASTRIPEC-I-trial), Ann Oncol, 32, S1040, 10.1016/j.annonc.2021.08.1485 Ichikawa, 2006, Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients, Ann Oncol, 17, 1665, 10.1093/annonc/mdl174 Özdemir, 2018, Sex differences in efficacy and toxicity of systemic treatments: an undervalued issue in the era of precision oncology, J Clin Oncol, 36, 2680, 10.1200/JCO.2018.78.3290 Unger, 2022, Sex differences in risk of severe adverse events in patients receiving immunotherapy, targeted therapy, or chemotherapy in cancer clinical trials, J Clin Oncol, 40, 1474, 10.1200/JCO.21.02377 Davidson, 2019, Influence of sex on chemotherapy efficacy and toxicity in oesophagogastric cancer: a pooled analysis of four randomised trials, Eur J Cancer, 121, 40, 10.1016/j.ejca.2019.08.010 Athauda, 2020, Impact of sex and age on chemotherapy efficacy, toxicity and survival in localised oesophagogastric cancer: a pooled analysis of 3265 individual patient data from four large randomised trials (OE02, OE05, MAGIC and ST03), Eur J Cancer, 137, 45, 10.1016/j.ejca.2020.06.005 Van Cutsem, 2006, Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 study group, J Clin Oncol, 24, 4991, 10.1200/JCO.2006.06.8429 Cunningham, 2008, Capecitabine and oxaliplatin for advanced esophagogastric cancer, N Engl J Med, 358, 36, 10.1056/NEJMoa073149 Bang, 2010, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive (ToGA): a phase 3, open-label, randomised controlled trial, Lancet, 376, 687, 10.1016/S0140-6736(10)61121-X